Tourbillon Capital Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Tourbillon Capital Partners’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-198,903	Closed	-$11.2M	–	81
2017 Q2	$11.2M	Sell	198,903 -330,000	-62%	-$13.2M	0.22%	59
2017 Q1	$20.7M	Buy	+528,903	New	+$16.8M	0.53%	44
2016 Q1	–	Sell	-663,982	Closed	-$34.2M	–	94
2015 Q4	$34.2M	Buy	663,982 +377,562	+132%	+$18.3M	0.76%	38
2015 Q3	$12.2M	Sell	286,420 -88,580	-24%	-$4.27M	0.32%	67
2015 Q2	$17.1M	Sell	375,000 -25,000	-6%	-$1.01M	0.37%	71
2015 Q1	$15.2M	Buy	+400,000	New	+$13.7M	0.39%	54

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tourbillon Capital Partners's PTLA Position: Q3 2017 in Review

Tourbillon Capital Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 198,903 shares — an estimated $11.2M sold.

Tourbillon Capital Partners first reported a position in PTLA in Q1 2015 and held it in 6 quarters. The position peaked at $34.2M in Q4 2015. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

Tourbillon Capital Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Tourbillon Capital Partners sold 198,903 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $11.2M.
Tourbillon Capital Partners first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 6 quarters.
Tourbillon Capital Partners's Portola Pharmaceuticals, Inc. position peaked at $34.2M in Q4 2015.
221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on Tourbillon Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.